BD Marks Hernia Mesh Milestone, Updates PREVENT Trial Enrollment

BD (Becton, Dickinson and Company) has revealed the first Phasix Mesh laparotomy reinforcement case recently was performed in Greece following the product’s expanded indication for prophylactic use in Europe. This initial treatment marks the first broad prophylactic indication of hernia mesh across open, high-risk procedures in the European Union, according to the company.

Surgeons completed the procedure at George Papanikolaou General Hospital of Thessaloniki, one of the largest institutions in northern Greece, led by general surgeon and associate professor, Ioannidis Orestis. The 63-year-old male patient (with multiple risk factors) underwent a sigmoidectomy, and doctors placed a Phasix Mesh (08 x 30 cm) prophylactically at the laparotomy incision site to reduce the likelihood of future hernia development.

Concurrently, BD’s PREVENT multicenter randomized controlled trial, conducted across sites in both Europe and the United States, has treated more than 85% of its target population and is projected to complete enrollment this year. The study aims to provide robust clinical evidence supporting prophylactic bioabsorbable mesh placement to reduce the incidence of incisional hernias, while also supporting a U.S. Food and Drug Administration PMA submission for an incisional hernia prevention indication in the United States.

“Incisional hernias affect up to 30% of patients after abdominal surgery and cost healthcare systems billions annually,” said Rian Seger, worldwide president of BD’s Surgery business. “With Phasix Mesh, we’re not just repairing hernias—we’re preventing them. This milestone reflects our commitment to improving long-term patient outcomes.”

According to recent U.K. data, patients who undergo incisional hernia repair incur an average cost of £23,148—nearly double that of patients who do not require repair. Prevention strategies have the potential to significantly reduce these costs and improve patient quality of life.

Phasix Mesh received CE marking approval for the prophylactic indication and launched three new sizes in 2025. The product is now registered in the United Kingdom and available across Europe for broad hernia prophylaxis indications, marking a pivotal step toward redefining surgical best practices, helping clinicians deliver safer outcomes and improve efficiency in every procedure. Phasix Mesh is not indicated for hernia prevention use in the United States.

BD is one of the world’s largest global medical technology companies; it is to improve medical discovery, diagnostics, and care delivery. The company develops technology, services, and solutions that help advance both clinical therapy for patients and clinical process for healthcare providers. BD and its more than 70,000 employees help enhance the safety and efficiency of clinicians’ care delivery processes, enable laboratory scientists to accurately detect disease, and advance researchers’ capabilities to develop the next generation of diagnostics and therapeutics. BD has a presence in virtually every country and partners with organizations worldwide to address challenging global health issues. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase efficiencies, improve safety, and expand healthcare access.